方丽兰 余更生 莫华贵 林秀欣 邓文静 周颖

【摘要】 目的：探究普萘洛尔联合埃克替尼治疗EGFR突变晚期非小细胞肺癌的临床效果。方法：选取2016年6月-2019年1月本院收治的80例EGFR突变晚期非小细胞肺癌患者，按照随机数字表法将患者分为对照组和治疗组，各40例。对照组口服埃克替尼治疗，治疗组口服普萘洛尔+埃克替尼治疗。比较两组患者的疗效、生活质量、毒副作用发生情况、肿瘤标志物变化情况、生存曲线。结果：治疗后，治療组的总缓解率和疾病控制率均高于对照组（P<0.05）;两组患者治疗后的生理状况、社会/家庭状况、与医生的关系、情感状况、功能状况和附加的关注情况评分均高于治疗前，且治疗组治疗后的上述评分均高于对照组，差异均有统计学意义（P<0.05）;治疗组的CEA、CYFRA21-1水平均低于对照组（P<0.05）;两组毒副作用发生率比较，差异均无统计学意义（P>0.05）。结论：普萘洛尔联合埃克替尼治疗EGFR突变晚期非小细胞肺癌效果明显，能有效提高患者的生活质量水平和生存率，降低患者血清肿瘤标志物，在临床上有一定的应用价值。

【关键词】 普萘洛尔 埃克替尼 EGFR突变 非小细胞肺癌

Clinical Study of Propranolol Combined with Ectinib in the Treatment of Advanced Non-small Cell Lung Cancer with EGFR Mutation/FANG Lilan， YU Gengsheng， MO Huagui， LIN Xiuxin， DENG Wenjing， ZHOU Ying. //Medical Innovation of China， 2021， 18（07）： -154

[Abstract] Objective： To explore the clinical study of propranolol combined with ectinib in the treatment of advanced non-small cell lung cancer with EGFR mutation. Method： A total of 80 patients with EGFR mutation advanced non-small cell lung cancer in our hospital from June 2016 to January 2019 were selected， they were randomly divided into control group and treatment group， 40 cases in each group. The control group was treated with Icotinib， the treatment group was treated with Propranolol and Icotinib. The efficacy， quality of life， occurrence of toxic and side effects， changes in tumor markers， survival curve of the two groups were compared. Result： After treatment， the total remission rate and disease control rate of the treatment group were higher than those of the control group （P<0.05）; the scores of physiological status， social/family status， relationship with doctors， emotional status， functional status and additional attention of the two groups after treatment were higher than those before treatment， and the above scores of the treatment group after treatment were higher than those of the control group， the differences were statistically significant （P<0.05）; the levels of CEA and CYFRA21-1 in the treatment group were lower than those in the control group （P<0.05）; there were no significant differences in the incidence of side effects between the two groups （P>0.05）. Conclusion： The combination of propranolol and ectinib in the treatment of EGFR-mutant advanced non-small cell lung cancer has obvious effects， can effectively improve the quality of life and survival rate of patients， and reduce serum tumor markers in patients， it has certain clinical application value.

[Key words] Propranolol Ectinib EGFR mutation Non-small cell lung cancer

First-authors address： Jiangmen Central Hospital， Jiangmen 529000， China

doi：10.3969/j.issn.1674-4985.2021.07.036

非小细胞肺癌（non-small cell lung cancer，NSCLC）是目前肿瘤疾病中发病率和死亡率均居首位的肿瘤疾病类型，其中晚期NSCLC的发生率占总患者人数的60%以上，且大多数患者被确诊时已属于肺癌晚期，确诊后有5年生存率的患者低于10%[1]。晚期NSCLC的传统治疗方法以化疗为主，治疗后患者的生存时间仅为10个月左右，疗效较为有限，其毒副作用的发生也使其在临床上的应用受到限制[2]。目前，靶向治疗方法的出现不仅提高了患者的生存期，而且对其生活质量有较大的改善作用[3]。以人表皮生长因子受体（epidermal growth factor receptor，EGFR）为靶点的治疗药物，是应用较多的分子靶向药物，其酪氨酸激酶抑制剂明显延长了肿瘤患者的生存期。靶向药物治疗非小细胞肺癌的临床研究已成为热点之一[4]。……